Bank of Montreal’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $494K | Hold |
33,868
| – | – | ﹤0.01% | 2474 |
|
|
2026
Q1 | $428K | Sell |
33,868
-3,616
| -10% | -$48.5K | ﹤0.01% | 2466 |
|
|
2025
Q4 | $591K | Buy |
37,484
+3,616
| +11% | +$45.9K | ﹤0.01% | 2229 |
|
|
2025
Q3 | $405K | Hold |
33,868
| – | – | ﹤0.01% | 2376 |
|
|
2025
Q2 | $256K | Buy |
33,868
+8,365
| +33% | +$50.3K | ﹤0.01% | 2663 |
|
|
2025
Q1 | $141K | Sell |
25,503
-6,245
| -20% | -$38.6K | ﹤0.01% | 2832 |
|
|
2024
Q4 | $183K | Buy |
+31,748
| New | +$304K | ﹤0.01% | 2792 |
|
|
2023
Q2 | – | Sell |
-66,967
| Closed | -$3.32M | – | 4054 |
|
|
2023
Q1 | $3.32M | Buy |
+66,967
| New | +$3.2M | ﹤0.01% | 1424 |
|
|
2022
Q3 | – | Sell |
-58,920
| Closed | -$2.69K | – | 4156 |
|
|
2022
Q2 | $2.69K | Buy |
58,920
+53,362
| +960% | +$2.9M | ﹤0.01% | 1746 |
|
|
2022
Q1 | $393K | Buy |
5,558
+690
| +14% | +$44.9K | ﹤0.01% | 3011 |
|
|
2021
Q4 | $366K | Sell |
4,868
-1,287
| -21% | -$101K | ﹤0.01% | 2615 |
|
|
2021
Q3 | $350K | Sell |
6,155
-415
| -6% | -$20.5K | ﹤0.01% | 3065 |
|
|
2021
Q2 | $318K | Buy |
6,570
+1,661
| +34% | +$81.3K | ﹤0.01% | 3037 |
|
|
2021
Q1 | $241K | Sell |
4,909
-217
| -4% | -$10.8K | ﹤0.01% | 3032 |
|
|
2020
Q4 | $249K | Buy |
5,126
+3,184
| +164% | +$140K | ﹤0.01% | 3102 |
|
|
2020
Q3 | $92K | Sell |
1,942
-359
| -16% | -$17.4K | ﹤0.01% | 3122 |
|
|
2020
Q2 | $117K | Buy |
2,301
+1,708
| +288% | +$88.4K | ﹤0.01% | 3017 |
|
|
2020
Q1 | $30K | Sell |
593
-2,049
| -78% | -$109K | ﹤0.01% | 3097 |
|
|
2019
Q4 | $163K | Buy |
2,642
+548
| +26% | +$34K | ﹤0.01% | 3272 |
|
|
2019
Q3 | $125K | Sell |
2,094
-206
| -9% | -$15.3K | ﹤0.01% | 3181 |
|
|
2019
Q2 | $194K | Buy |
2,300
+1,529
| +198% | +$138K | ﹤0.01% | 2938 |
|
|
2019
Q1 | $74K | Sell |
771
-99
| -11% | -$8.88K | ﹤0.01% | 3195 |
|
|
2018
Q4 | $61K | Buy |
870
+216
| +33% | +$16.6K | ﹤0.01% | 3197 |
|
|
2018
Q3 | $56K | Sell |
654
-19,428
| -97% | -$1.95M | ﹤0.01% | 3342 |
|
|
2018
Q2 | $2.33M | Sell |
20,082
-6,925
| -26% | -$691K | ﹤0.01% | 1575 |
|
|
2018
Q1 | $2.19M | Sell |
27,007
-12,555
| -32% | -$966K | ﹤0.01% | 1524 |
|
|
2017
Q4 | $2.32M | Buy |
39,562
+4,306
| +12% | +$216K | ﹤0.01% | 1516 |
|
|
2017
Q3 | $1.65M | Buy |
+35,256
| New | +$1.42M | ﹤0.01% | 1707 |
|
|
2017
Q2 | – | Sell |
-3,221
| Closed | -$98K | – | 4180 |
|
|
2017
Q1 | $98K | Sell |
3,221
-463
| -13% | -$14.4K | ﹤0.01% | 2834 |
|
|
2016
Q4 | $116K | Buy |
3,684
+732
| +25% | +$21K | ﹤0.01% | 2759 |
|
|
2016
Q3 | $78K | Buy |
+2,952
| New | +$68.6K | ﹤0.01% | 2898 |
|
|
2016
Q2 | – | Sell |
-859
| Closed | -$25K | – | 4144 |
|
|
2016
Q1 | $25K | Buy |
+859
| New | +$23.9K | ﹤0.01% | 3312 |
|
|
2015
Q4 | – | Sell |
-2,296
| Closed | -$83K | – | 4269 |
|
|
2015
Q3 | $83K | Buy |
+2,296
| New | +$98.6K | ﹤0.01% | 2714 |
|
|
2015
Q2 | – | Sell |
-87
| Closed | -$3K | – | 3966 |
|
|
2015
Q1 | $3K | Buy |
+87
| New | +$3.38K | ﹤0.01% | 3709 |
|
|
2014
Q3 | – | Sell |
-90
| Closed | -$4K | – | 4114 |
|
|
2014
Q2 | $4K | Buy |
+90
| New | +$3.43K | ﹤0.01% | 4246 |
|
Other funds holding ENTA
JT
KAM
FCM
DTC
ACM
SSC
Bank of Montreal's ENTA Position: Q2 2026 in Review
Bank of Montreal held its Enanta Pharmaceuticals (ENTA) position steady in Q2 2026 at 33,868 shares worth $494K. The position accounts for ﹤0.01% of the portfolio, ranked #2474.
Bank of Montreal first reported a position in ENTA in Q2 2014 and has held it in 35 quarters since. The position peaked at $3.32M in Q1 2023. 116 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.
- Bank of Montreal held 33,868 shares of Enanta Pharmaceuticals worth $494K as of Q2 2026.
- Bank of Montreal left its Enanta Pharmaceuticals share count unchanged in Q2 2026.
- Enanta Pharmaceuticals made up ﹤0.01% of Bank of Montreal's portfolio in Q2 2026, its #2474 holding.
- Bank of Montreal first reported a position in Enanta Pharmaceuticals in Q2 2014 and has held it in 35 quarters since.
- Bank of Montreal's Enanta Pharmaceuticals position peaked at $3.32M in Q1 2023.
- 116 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.
Based on Bank of Montreal's 13F filing for Q2 2026, filed 12 Aug 2026.